Long-term follow-up of children with high-risk neuroblastoma: The ENSG5 trial experience

Pediatric Blood and Cancer

Volumn 60, Issue 7, 2013, Pages 1135-1140

  Moreno, Lucas ^a   Vaidya, Sucheta J ^a   Pinkerton, C Ross ^b   Lewis, Ian J ^c   Imeson, John ^d   Machin, David ^d   Pearson, Andrew D J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Royal Children's and Mater Children's Hospitals   (Australia)

^c ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Late effects; Long term survivors; Neuroblastoma; Second malignancies

Indexed keywords

MELPHALAN;

ADOLESCENT; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DELAYED PUBERTY; DISEASE SEVERITY; EPENDYMOMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEARING IMPAIRMENT; HUMAN; HYPOGLYCEMIA; HYPOGONADISM; INDUCTION CHEMOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROBLASTOMA; OSTEOSARCOMA; PAROTID GLAND; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHOOL CHILD; SECOND CANCER;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; NEOPLASMS, SECOND PRIMARY; NEUROBLASTOMA; SURVIVORS; TIME; YOUNG ADULT;

EID: 84878220353     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24452     Document Type: Article

References (33)

1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-2120.
2. Modak S, Kushner BH, LaQuaglia MP, et al. Management and outcome of Stage 3 neuroblastoma. Eur J Cancer 2009;45:90-98.
3. Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010;363:1313-1323.
4. Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: Results of Children's Oncology Group Study, p. 964. J Clin Oncol 2012;30:1842-1848.
5. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
6. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 2009;27:1007-1013.
7. Pritchard J, Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ensg-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005;44:348-357.
8. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: Comparable results with three consecutive high-dose protocols adopted by the Italian Co-operative Group for neuroblastoma. J Clin Oncol 2003;21:1592-1601.
9. Cohn SL, Pearson AD, London WB, et al. The international neuroblastoma risk group (inrg) classification system: An inrg task force report. J Clin Oncol 2009;27:289-297.
10. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-gd2 antibody with gm-csf, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-1334.
11. Berthold F, Hero B, Kremens B, et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with Stage 4 neuroblastoma over 1 year of age. Cancer Lett 2003;197:11-17.
12. Cotterill SJ, Pearson AD, Pritchard J, et al. Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: A report from the European Neuroblastoma Study Group "Survey". Med Pediatr Oncol 2001;36:235-238.
13. Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011;11:21.
14. Laverdiere C, Cheung NK, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005;45:324-332.
15. Perwein T, Lackner H, Sovinz P, et al. Survival and late effects in children with Stage 4 neuroblastoma. Pediatr Blood Cancer 2011;57:629-635.
16. de Vathaire F, Hawkins M, Campbell S, et al. Second malignant neoplasms after a first cancer in childhood: Temporal pattern of risk according to type of treatment. Br J Cancer 1999;79:1884-1893.
17. Kushner BH, Kramer K, Modak S, et al. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009;53:17-22.
18. Kushner BH, Cheung NK, Kramer K, et al. Neuroblastoma and treatment-related myelodysplasia/leukemia: The memorial sloan-kettering experience and a literature review. J Clin Oncol 1998;16:3880-3889.
19. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 2006;24:476-483.
20. van Santen HM, de Kraker J, Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005;41:1767-1774.
21. Gurney JG, Tersak JM, Ness KK, et al. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics 2007;120:e1229-e1236.
22. Trahair TN, Vowels MR, Johnston K, et al. Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant 2007;40:741-746.
23. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006;24:2891-2896.
24. Hobbie WL, Moshang T, Carlson CA, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 2008;51:679-683.
25. Laverdiere C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: A report from the childhood cancer survivor study. J Natl Cancer Inst 2009;101:1131-1140.
26. Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with Stage 4 neuroblastoma: A randomised trial. Lancet Oncol 2008;9:247-256.
27. CTEP. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf [Accessed November 27, 2012].
28. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 1991;19:295-300.
29. Skinner R, Parry A, Price L, et al. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors. Eur J Cancer 2009;45:3213-3219.
30. Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al. Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation. Bone Marrow Transplant 1999;24:1131-1136.
31. Flandin I, Hartmann O, Michon J, et al. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the french society of pediatric oncology. Int J Radiat Oncol Biol Phys 2006;64:1424-1431.
32. Rubino C, Adjadj E, Guerin S, et al. Long-term risk of second malignant neoplasms after neuroblastoma in childhood: Role of treatment. Int J Cancer 2003;107:791-796.
33. Garaventa A, Gambini C, Villavecchia G, et al. Second malignancies in children with neuroblastoma after combined treatment with 131i-metaiodobenzylguanidine. Cancer 2003;97:1332-1338.